Lates News

Before the market opened, Lilly's US stocks fell nearly 4% while Novo Nordisk rose over 2%. According to the latest prescription data, Lilly's new weight loss drug, Foundayo, had a slow start after its launch. This is an early sign that the company will face challenges in trying to catch up with the competitor Novo Nordisk. Canadian Royal Bank Capital Markets analyst Trung Huynh cited data from IQVIA, stating that Foundayo only had 3,707 prescriptions in its second week on the market. In comparison, Novo Nordisk's oral version of Wegovy had a total of 18,410 prescriptions in its second week on the market.